Search results for "Visual Acuity"

showing 10 items of 456 documents

INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retin…

2016

To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB).Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1.25 mg of IVB and had a minimum follow-up of 60 months. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.Two hundred and forty-seven consecutive patients (292 eyes) were included. The mean number …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabVisual AcuityAngiogenesis InhibitorsOphthalmoscopy03 medical and health sciencesMacular Degeneration0302 clinical medicineOphthalmologyGeographic AtrophymedicineHumans030212 general & internal medicineFluorescein AngiographyAfliberceptAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryGeneral MedicineMacular degenerationMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesChoroidal NeovascularizationBevacizumabOphthalmoscopyOphthalmologyChoroidal neovascularizationTreatment OutcomeIntravitreal Injections030221 ophthalmology & optometryFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drugRetina (Philadelphia, Pa.)
researchProduct

Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.

2010

PURPOSE The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuitymonoclonalAngiogenesis InhibitorsAntibodies Monoclonal HumanizedLoading doseChoroidal neovascularization; male; treatment outcome; injections; middle aged; vascular endothelial growth factor a; female; vitreous body; humans; retreatment; visual acuity; angiogenesis inhibitors; aged; angioid streaks; antibodies monoclonalInjectionsNeovascularizationOptical coherence tomographyOphthalmologyRanibizumabMedicineantibodiesHumansANTI-VEGFAgedintravitreal ranibizumabmedicine.diagnostic_testbusiness.industrySettore MED/30 - Malattie Apparato VisivoAntibodies MonoclonalGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseeye diseasesChoroidal NeovascularizationVitreous BodyOphthalmologyAngioid streaksChoroidal neovascularizationTreatment OutcomeRetreatmentAngioid StreaksFemalemedicine.symptomRanibizumabbusinessAngioid streak-related choroidal neovascularizationmedicine.drugRetina (Philadelphia, Pa.)
researchProduct

Best-corrected visual acuity and retinal thickness are associated with improved cortical visual processing in treated wet AMD patients

2015

Purpose In response to anti-VEGF treatment for wet AMD retinal anatomy and visual acuity is often remedied. In our previous study, we showed that visual evoked potentials (VEP) improve following successful anti-VEGF treatment. The aim of this study was to investigate, how visual acuity and retinal thickness changes are reflected in VEP parameters. Moreover, we wanted to assess the feasibility of VEP as a novel monitoring tool for wet AMD patients. Methods A total of 16 patients and six control subjects were enrolled in this study. Patients received three bevacizumab intravitreal injections. At the beginning of the study and four to 6 weeks after the last injection, the best-corrected visual…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresexudative age-related macular degenerationvisual acuityAngiogenesis InhibitorsVisual systemRetinaVisual processingchemistry.chemical_compoundOphthalmologyMedicineHumansVisual PathwaysProspective Studiesage-related eye diseasesProspective cohort studyAgedVisual CortexBest corrected visual acuityAged 80 and overRetinaoptical coherence tomographybusiness.industryRetinalta3141General MedicineOrgan Sizeeye diseasesta3125BevacizumabOphthalmologymedicine.anatomical_structureVisual cortexchemistryIntravitreal InjectionsWet Macular DegenerationOptometryEvoked Potentials VisualFemalesense organsmedicine.symptomvisual evoked potentialbusinessTomography Optical CoherenceActa Ophthalmologica
researchProduct

Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular ede…

2013

To evaluate the anatomical and functional outcomes at 24 months in patients with diffuse diabetic macular edema treated with primary intravitreal bevacizumab (IVB) plus grid laser photocoagulation (GLP) or primary IVB alone or GLP alone.Retrospective, interventional, comparative, multicenter study. We included in this analysis 141 eyes of 120 patients with diffuse diabetic macular edema treated with primary IVB alone (Group A), 120 eyes of 94 patients with GLP therapy (Group B), and 157 eyes of 104 patients treated with IVB plus GLP (Group C).In all 3 groups, the authors observed improvement of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity from baseline to 24-month…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresDiabetic macular edemaVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular EdemaOphthalmologymedicineHumansIn patientIntravitreal bevacizumabRetrospective StudiesRetinaDiabetic RetinopathyLaser Coagulationbusiness.industryGeneral MedicineMiddle AgedCombined Modality Therapyeye diseasesbody regionsBevacizumabOphthalmologymedicine.anatomical_structureTreatment OutcomeIntravitreal InjectionsFemalesense organsbusinessTomography Optical CoherenceRetina (Philadelphia, Pa.)
researchProduct

Is Ranibizumab effective in stopping the loss of vision for Choroidal Neovascularization in Pathologic Myopia? A Long Term Follow-up Study

2010

Aim To assess the efficacy and safety of ranibizumab in the treatment of choroidal neovascularisation (CNV) caused by pathologic myopia (PM). Design Prospective, multicentre, interventional case series. Methods 40 eyes of 39 consecutive patients with PM and CNV were treated with ‘on demand’ intravitreal injection of ranibizumab 0.5 mg. Final best corrected visual acuity (BCVA) and its change from baseline were the main outcome measures. Changes in optical coherence tomography (OCT) central retinal thickness (CRT) were a secondary outcome. Results Mean age was 53±13 years and mean refractive error –13.5±6.5 D. Median follow-up was 13.3±2 (range 12–18) months. Fifteen eyes (37.5%) had previou…

MaleVisual Acuity/drug effectsRefractive errorgenetic structuresEye diseaseVisual AcuityVision disorderProspective StudiesFluorescein AngiographyMedicine(all)Neovascularisationmedicine.diagnostic_testAntibodies MonoclonalDrugsDiabetic retinopathyMiddle AgedFluorescein angiographySensory SystemsChoroidal neovascularizationmedicine.anatomical_structureMyopia DegenerativeIntravitreal InjectionsFemaleMyopia Degenerative/complicationsmedicine.symptomTomography Optical Coherencemedicine.drugAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedAntibodies Monoclonal/administration & dosageCellular and Molecular NeuroscienceRanibizumabOphthalmologymedicineHumansAgedbusiness.industryChoroidChoroidal Neovascularization/drug therapyOff-Label Usemedicine.diseaseChoroidal Neovascularizationeye diseasesOphthalmologyChoroidsense organsRanibizumabaged 80 and overbusinessFollow-Up Studies
researchProduct

Retroespalhamento luminoso das córneas de pacientes com diabete melito dependente e não dependente de insulina: estudo piloto

2017

ABSTRACT Purpose: To compare central corneal backscatter obtained from Scheimpflug images between patients with insulin-dependent and non-insulin-dependent diabetes mellitus (IDDM and NIDDM, respectively) and healthy controls. Methods: Seven patients with IDDM (7 eyes), eleven patients with NIDDM (11 eyes), and sixteen healthy subjects (16 eyes) were included in this pilot study. Scheimpflug imaging system (Pentacam, Oculus Inc., Germany) was used to obtain optical sections of the cornea. Seven meridians were analyzed for each eye, oriented from 70° to 110°. Optical density values for the central 3-mm and 5-mm zones of the cornea were obtained by image analysis using external software. Resu…

MaleVisual acuityCorneal Pachymetrygenetic structuresScheimpflug principleVisual AcuityPilot ProjectsDiagnostic Techniques OphthalmologicalCorneal DiseasesCornea0302 clinical medicineDiabetes mellituslcsh:OphthalmologyReference ValuesCorneaMedicineCorneal pachymetrymedicine.diagnostic_testCorneal DiseasesAge FactorsScheimpflug imagingGeneral MedicineMiddle AgedCorneal topographymedicine.anatomical_structureDiabetes mellitus tipo 2Diabetes mellitus tipo 1Femalemedicine.symptomAdultmedicine.medical_specialtyProjetos pilotoStatistics Nonparametric03 medical and health sciencesAnterior Eye SegmentDiabetes mellitusOphthalmologyHumansScheimpflug Topografia da córneaAgedbusiness.industryCase-control studyReproducibility of ResultsDiabetes mellitus type 1Diabetes mellitus type 2medicine.diseaseeye diseasesOphthalmologyPilot projectDiabetes Mellitus Type 1Diabetes Mellitus Type 2lcsh:RE1-994Case-Control Studies030221 ophthalmology & optometrysense organsCorneal topographybusiness030217 neurology & neurosurgery
researchProduct

Comparing oculomotor efficiency and visual attention between drivers and non-drivers through the Adult Developmental Eye Movement (ADEM) test: A visu…

2021

Objective The objective of this study was to assess and compare drivers’ and non-drivers’ outcomes in the Adult Developmental Eye Movement test (ADEM), a visual-verbal test that measures the time needed to read series of numbers in both a vertical and horizontal reading pattern. A set of driving parameters (i.e., experience, risk exposure, and day and night perceived difficulty) and demographic variables (i.e., age, gender, and academic level) were considered as potential predictors of the test performance. Methods For this cross-sectional study, 302 healthy subjects (age range 20 to 86 years old) completed a self-reported questionnaire aimed at retrieving data on the independent variables…

MaleVisual acuityEye MovementsLightVisionPhysiologyVisual SystemEpidemiologySensory PhysiologyVisual AcuitySocial SciencesAudiology0302 clinical medicineSociologyAtencióSurveys and QuestionnairesTask Performance and AnalysisMedicine and Health SciencesPsychologyAttentionmedia_commonVisual ImpairmentsAged 80 and overMultidisciplinary05 social sciencesQRMiddle AgedSensory SystemsTest (assessment)OftalmologíaMedicineSensory PerceptionFemalemedicine.symptomPsychologyResearch ArticleAdultAutomobile Drivingmedicine.medical_specialtymedia_common.quotation_subjectScienceEducationYoung Adult03 medical and health sciences0502 economics and businessLinear regressionmedicineOptometríaHumansVisual attentionVisióSet (psychology)Educational AttainmentNight VisionVision OcularAged050210 logistics & transportationVariablesCognitive PsychologyBiology and Life SciencesEye movementSaccadic maskingOphthalmologyCross-Sectional StudiesAge GroupsMedical Risk FactorsPeople and PlacesCognitive SciencePerceptionPopulation Groupings030217 neurology & neurosurgeryNeuroscience
researchProduct

Visual function comparison of 2 aspheric multifocal intraocular lenses

2011

To compare visual function after bilateral implantation of the multifocal Lentis Mplus LS-312 with a nonrotational symmetrical design (copolymer aspheric) or the Acrysof Restor SN6AD1 +3.0 D (hybrid aspheric) intraocular lens (IOL).Fernández-Vega Ophthalmological Institute, Oviedo, Spain.Comparative case series.Six months postoperatively, corrected distance visual acuity (CDVA), distance-corrected near visual acuity (DCNVA), the defocus curve, and photopic and mesopic contrast sensitivity with and without glare were measured.The mean CDVA was 0.02 ± 0.06 (SD) with the copolymer aspheric IOL and -0.06 ± 0.05 logMAR with the hybrid aspheric IOL (P=.07) and the mean DCNVA, 0.10 ± 0.06 and -0.0…

MaleVisual acuityPseudophakiagenetic structuresMesopic visionmedicine.medical_treatmentmedia_common.quotation_subjectVisual AcuityIntraocular lensGlareContrast SensitivityLens Implantation IntraocularmedicineHumansContrast (vision)Prospective StudiesMathematicsmedia_commonLenses IntraocularPhacoemulsificationGlare (vision)Middle AgedMultifocal intraocular lenseye diseasesSensory SystemsOphthalmologyVisual functionOptometryFemaleSurgerysense organsmedicine.symptomPhotopic visionJournal of Cataract and Refractive Surgery
researchProduct

Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome

2015

Purpose To report the incidence and characteristics of endophthalmitis after intravitreal injections of anti–vascular endothelial growth factor agents or corticosteroids and to describe the clinical and bacteriologic characteristics, management, and outcome of these eyes with acute endophthalmitis in France. Design Retrospective, nationwide multicenter case series. Methods From January 2, 2008 to June 30, 2013, a total of 316 576 intravitreal injections from 25 French ophthalmic centers were included. For each center, the number of intravitreal injections was determined using billing codes and the injection protocol was recorded. A registry and hospital records were reviewed to identify pat…

MaleVisual acuityfactor agentsVisual AcuityAngiogenesis InhibitorsEye Infections BacterialEndophthalmitisAntisepticRisk Factorscausative organismsrisk-factorsAged 80 and overEndophthalmitis[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyIncidence (epidemiology)IncidenceMiddle AgedAnti-Bacterial Agents[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansIntravitreal InjectionsFemaleFrancePresentation (obstetrics)medicine.symptommetaanalysisAdultmedicine.medical_specialtymacular degenerationmedicine.drug_classRetinal DiseasesmedicineHumansranibizumab[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansGlucocorticoidsAgedRetrospective Studiesocular surfaceBacteriabusiness.industryRetrospective cohort studyantibiotic-prophylaxisEye infectionmedicine.diseaseConfidence intervalSurgeryVitreous BodyOphthalmologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyoperating-roomendothelial growth-factor
researchProduct

Visual acuity and color discrimination in patients with cataracts.

2020

Color vision tests can give information about pathological changes in eye structures. The purpose of our research was to study the color vision sensitivity and visual acuity changes before and after cataract surgery. We used a saturated Farnsworth D15 color vision arrangement test to check color sensitivity changes in confusion line directions. The test is easily perceptible (essential to eldery patients), and it is possible to check color sensitivity changes in tritan, protan, and deutan confusion line directions. The results were analyzed in several ways: by summing the color differences between adjacent caps according to Bowman and averaging the color difference vectors according to Ving…

MaleVisual acuitygenetic structuresColor visionmedicine.medical_treatmentVisual Acuity01 natural sciencesColor discriminationCataract010309 opticsOpticsCataracts0103 physical sciencesmedicineHumansIn patientChromatic scaleLeast-Squares AnalysisMathematicsAgedColor differencebusiness.industryCataract surgerymedicine.diseaseeye diseasesAtomic and Molecular Physics and OpticsElectronic Optical and Magnetic MaterialsOptometryRegression AnalysisFemalesense organsComputer Vision and Pattern Recognitionmedicine.symptombusinessColor PerceptionJournal of the Optical Society of America. A, Optics, image science, and vision
researchProduct